Physician profile

Leigh Ann Obanion

Vascular Surgery · Fresno, CA

NPI 1194023259

$469,132.40

in general payments reported to CMS, 2019-2025

21 companies · $199K in 2025

The $199K reported for 2025 was more than what 99% of Vascular Surgery providers received nationally (typical 2025 total: $927).

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$176,732.50
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program$68,600.00
Travel and Lodging$62,542.12
Food and Beverage$44,308.39
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$34,425.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Shockwave Medical, INC $302,845.45 2020-2025 Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter
Medtronic, INC. $68,136.58 2021-2025 Venaseal, Heli-Fx Endoanchor System, In.Pact Admiral
W. L. Gore & Associates, INC. $32,525.64 2019-2025 Product In Development, Gore Viabahn Vbx Balloon Expandable Endo, Gore Excluder Iliac Branch Endoprosthesis
Penumbra, INC. $30,793.64 2023-2025 Indigo System, Penumbra System, Smart Coil
Medtronic Vascular, INC. $25,193.00 2019-2020
Abbott Laboratories $6,073.58 2019-2025 Amplatzer Amulet, Esprit
Silk Road Medical, INC. $2,284.15 2020-2024 Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter
Cook Medical LLC $299.80 2021-2023 Zilver Ptx
Inari Medical, INC. $148.12 2021-2022
Boston Scientific Corporation $146.82 2021-2024 Ranger
Humacyte Global, INC. $145.32 2025 Symvess
Dilon Technologies, INC. $120.92 2025 Hemoblast Bellows
Globus Medical, INC. $104.02 2024 Alif
Janssen Pharmaceuticals, INC $77.06 2019-2023 Xarelto
E.R. Squibb & Sons, L.L.C. $63.54 2021-2022
Show all 21 companies
CompanyGeneral paymentsYearsTop products
Reflow Medical INC $60.67 2025
Bolton Medical INC $46.78 2021-2023 Treo Abdominal Stent-Graft System
Cordis US Corp. $19.90 2022
Urgo Medical North America, LLC $18.95 2024 Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap
Balt USA, LLC $14.93 2022
Novo Nordisk INC $13.53 2023

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$1,000.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Leigh Ann Obanion

$469,132.40

in general payments reported 2019-2025

Years
2019-2025
Top company
Shockwave Medical, INC
Context
The $199K reported for 2025 was more than what 99% of Vascular Surgery providers received nationally (typical 2025 total: $927).

https://glasscript.com/doctor/3995680/leigh-ann-obanion

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.